MDT
NYSE · Health Care
Medtronic Plc
$78.81
-2.12 (-2.62%)
MDT News16 articles
Medtronic Stock Edges Up on Earnings Beat, Tariff Warning Looms
Medtronic shares slipped 0.32% to $81.67 Friday after a post-earnings rally, as strong Q4 revenue growth and a dividend hike were offset by a $250 million tariff hit and profit guidance below consensus.
Medtronic Shares Surge on Strong Q4, Guidance Weighs
Medtronic shares jumped 5.4% after beating Q4 estimates on strong heart-device sales, but fiscal 2027 guidance missed due to tariff and diabetes split uncertainty.
Medtronic Surges on Strong Heart-Device Sales, But 2027 Profit Outlook Caps Gains
Medtronic shares surged 5.1% after beating Q4 estimates, fueled by 78% cardiac ablation growth, but gains were capped by a weak 2027 profit outlook and tariff concerns.
Boston Scientific Tumbles 16% on Watchman Slowdown; Focus Shifts to Monday's Reaction
Boston Scientific shares fell 16.4% last week after CEO Michael Mahoney warned of declining Watchman usage and flat growth through Q3. Wells Fargo downgraded the stock and slashed its price target.
Intuitive Surgical Dips Despite Record Highs for Nasdaq and S&P 500
Intuitive Surgical shares slipped 3.1% last week to $424.64, even as the Nasdaq and S&P 500 reached new records. Q1 revenue rose 23% to $2.77 billion, but tariff risks and a drop in bariatric procedures kept investors cautious.
Medtronic Stock Drops 6% Ahead of Earnings Report
Medtronic shares fell 6.1% last week to $73.81 ahead of its fiscal Q4 earnings on June 3. Options imply a 4.1% move. The company recently agreed to buy SPR Therapeutics for $650 million.
Intuitive Surgical Dips on Goldman Sachs Price Target Cut Amid Medtech Weakness
Intuitive Surgical shares slid over 4% after Goldman Sachs cut its price target to $558. The medtech giant posted strong Q1 revenue growth but faces tariff and competitive headwinds.
Boston Scientific Plunges to Two-Year Low on Watchman Slowdown
Boston Scientific shares fell 10% to a two-year low after CEO Michael Mahoney flagged slower use of its Watchman heart implant, raising growth concerns.
Medline's $2.7B Secondary Offering Tests Post-IPO Demand
Medline's $2.68 billion secondary offering, upsized from 60 million shares, prices at $37 each, with the stock holding near that level.
Medtronic Hovers Near 52-Week Low as Market Awaits Earnings
Medtronic shares closed at $76.15, near their 52-week low, as broader market weakness weighed ahead of the company's June 3 earnings report.
Intuitive Surgical Drops to 52-Week Low on Recall and Competition Fears
Intuitive Surgical shares fell to a 52-week low Monday after an FDA recall and lowered procedure growth forecasts, overshadowing a strong Q1 earnings beat.
Intuitive Surgical Hits 52-Week Low on FDA Class I Recall, Tariff Worries
Intuitive Surgical shares dropped 6.6% to a 52-week low after the FDA classified a recall of its SureForm stapler reloads as Class I, citing four injuries and one death. Strong Q1 earnings were overshadowed by tariff and safety concerns.
Intuitive Surgical Shares Surge on Upgraded Forecast, Robust da Vinci Sales
Intuitive Surgical shares climbed to $482.22 after the company raised its 2026 growth outlook and reported a 23% revenue jump to $2.77 billion in Q1, driven by strong da Vinci system placements.
Tech Stocks Drive Market Gains Amid Ceasefire Relief and Earnings Strength
U.S. stocks climbed Wednesday, with the Nasdaq leading gains as technology shares rallied following an extended Iran ceasefire and a wave of corporate earnings. Oil prices remained elevated near $100 a barrel.
Danaher Shares Slip Ahead of Holiday, Traders Eye PCE Data
Danaher shares fell in extended trading Friday, closing near $212.58. The dip precedes a market holiday, with attention shifting to next week's key inflation report.
Boston Scientific Shares Extend Decline Amid Electrophysiology Concerns
Boston Scientific stock fell 2.6% in Monday trading, continuing last week's selloff as investors scrutinize the company's heart-rhythm device segment and Watchman demand.